Amgen Issues Presentation of Results from Phase 3 Study Showing Clinical Equivalence of ABP 501 with Adalimumab
November 09, 2015 at 17:32 PM EST
Amgen (NASDAQ: AMGN) today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and ...